Phantom Limb
Conditions
Keywords
Phantom Limb, Genetic Variation, DNA Sequence Analysis, Amputation, Traumatic, Single Nucleotide Polymorphism, Visual Analog Pain Scale, Brain-Derived Neurotrophic Factor, Inflammatory Antibody, Peripheral Nerve Damage
Brief summary
The purpose of this study is to determine if there is a genetic component to phantom limb pain. DNA will be analyzed for single nucleotide polymorphisms (SNPs) between the control and phantom limb pain group. Total RNA will also be isolated and profiled to asses the degree to which our gene(s) of interest are expressed in the presence or absence of phantom limb pain. Some proteins, such as inflammatory antibodies or the neurotrophin brain-derived neurotrophic factor (BDNF), will also be assessed for their association(s) with phantom limb pain.
Detailed description
Most patients (90-95%)with major limb amputations experience a phantom limb--the vivid impression that the limb is still present. In many cases, the sensation is painful for reasons that are currently not well understood. A small subset of amputees (\<10%) never experience phantom limb pain (PLP), the painful sensation felt in the amputated limb. This difference suggests that there may be a genetic component that precludes some patients from ever experiencing PLP. Understanding the genetic components of PLP may help in predicting which patients will experience PLP and which amputees will respond to the various treatment options available. In order to understand the genetic aspects and ultimately develop more effective treatment options in the future, patients with and without PLP will be asked to give 30 mls of blood after overnight fasting. These blood samples will be de-identified and sent to the National Institutes of Health (NIH) in Bethesda, Maryland, where all of the genetic analyses will take place.
Interventions
PROCEDUREBlood Draw
Single blood draw of 30 ml
Sponsors
Uniformed Services University of the Health Sciences
Henry M. Jackson Foundation for the Advancement of Military Medicine
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Chronic PLP Group: * At least 18 years of age. * Written informed consent and written authorization for use or release of health and research study information * Single or multiple upper and/or lower limb amputation * At least three months post-amputation * Ability to follow study instructions and likely to complete required visit(s) * Experienced PLP for at least one month and at least 3 times per week * Phantom limb pain differentiated from residual limb pain by physical exam. * Subjects taking blood thinners or other medications that do not increase risk during a blood draw. Non-Chronic PLP Group: * At least 18 years of age. * Written informed consent and written authorization for use or release of health and research study information * Single or multiple upper and/or lower limb(s) amputation * At least three months post-amputation * Ability to follow study instructions and likely to complete required visit(s) * Experienced PLP less than 10 times total and/or for less than two weeks * Subjects taking blood thinners or other medications that do not increase risk during a blood draw.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identification of Unique Single Nucleotides Polymorphisms (SNPs) associated with Phantom Limb Pain (PLP) | 5 years | The primary outcome measure for this study is the identification of unique SNPs that may correlate with PLP. Patients will undergo a one-time blood draw and fill out a survey characterizing their phantom limb pain. The PLP characteristics along with DNA analysis using Affymetrix SNP chip technology will be used to match genotype with phenotype. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation between Phantom Limb Pain (PLP) and Blood Levels of Antibodies Associated with Peripheral Nerve Damage | 5 years | The underlying hypothesis of the secondary outcome measure is that damage to peripheral nerves provokes a humoral immune response to neuronal and glial proteins that can be detected by measuring specific antibodies in blood. The data obtained will lead to a more complete understanding of pathogenic mechanisms in PLP and potential biomarkers for sub-classification, prognosis, and intervention. |
| Correlation between Phantom Limb Pain (PLP) and Serum Levels of Brain-derived Neurotrophic Factor (BDNF) | 5 years | BDNF has been implicated in pain nociception and is therefore pertinent to our study of phantom limb pain. After peripheral nerve injury, BDNF expression is dramatically increased in pain receptors of the brainstem. |
| Correlation between Phantom Limb Pain (PLP) and Unique Transcribed RNA | 5 years | Many underlying causes for neuropathic pain involve changes in messenger ribonucleic acid (mRNA) levels because of altered gene expression or transcript stability. The study will isolate total RNA from blood and measure the relative amounts of transcribed RNA under the condition of phantom limb pain or no phantom limb pain. |
Countries
United States
Outcome results
None listed